New initiative identifies key parameters Inherent effective anti-tumor immunity Kumar Jeetendra | October 10, 2020 Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies. Targeting the”right” neoantigens – at a cancer vaccine or a cell treatment – has the promise to eliminate a patient’s cancer with minimal side effects. But countless mutations can exist in …
Drug used to control pulse may improve malignant growth patients’ reaction to immunotherapy Kumar Jeetendra | November 1, 2020 The exact same biochemical triggers which spur a”flight or fight” reaction once we encounter threats may help tumor cells to thrive. A group of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to interrupt that dynamic so that cancer therapies can be effective. Their latest work, published today in Clinical Cancer Research, …
What is Hybridoma Technology and Why is it Important? Kumar Jeetendra | November 16, 2024 Hybridoma technology is a unique technique that has enabled the generation of clones of cells that produce identical antibodies, and is a wide used throughout the world as an efficient method for the rabid production of monoclonal antibodies. This technique was refined in the 1970s by César Milstein and Georges Köhler, since then it has …
Alembic Gets USFDA Nod for Doxorubicin Liposome Injection Kumar Jeetendra | June 30, 2025 30th June, 2025 Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxorubicin Hydrochloride Liposome Injection, 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials. The approved ANDA is therapeutically equivalent …
